Across TCGA pan-cancer cohorts, TAF13 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated TAF13 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher TAF13 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TAF13 expression acts as an unfavorable survival marker.
COAD are the cancer types where TAF13 Mutation most reproducibly stratifies survival.